



NAIL DISORDERS

ADVERSE NAIL REACTIONS WITH CHEMOTHERAPEUTIC AGENTS

Ellen Roh⁽¹⁾

Massachusetts General Hospital, Harvard Medical School, Boston, United States⁽¹⁾

Background/Observation: As of 2018, there are more than 150 chemotherapeutic agents that have been approved by the US Food and Drug administration. It is well-known that rashes are a common adverse effect of these medications, with cutaneous complications affecting up to 90% of patients exposed to the targeted therapy subset. These rashes are well-documented, including recommendations for diagnosis and management.

Though not as frequent, nail involvement can also occur with many chemotherapeutic agents, and can be a source of emotional distress, discomfort and morbidity. Side effects range from the cosmetically disruptive Beau's lines that can occur with cytotoxic drugs to the painful onycholysis seen with the taxanes to EGFR inhibitor-associated paronychias, which can become secondarily infected.

This presentation will review nail changes associated with chemotherapy and immunotherapy, specifically discussing the relevant clinical findings and treatment options.

Key message: This presentation will review nail changes associated with chemotherapy and immunotherapy, specifically discussing the relevant clinical findings and treatment options.

